311 related articles for article (PubMed ID: 15963813)
1. An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines.
Smith JA; Ngo H; Martin MC; Wolf JK
Gynecol Oncol; 2005 Jul; 98(1):141-5. PubMed ID: 15963813
[TBL] [Abstract][Full Text] [Related]
2. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
[TBL] [Abstract][Full Text] [Related]
3. Current status of taxane and platinum-based chemotherapy in ovarian cancer.
McGuire WP
J Clin Oncol; 2003 May; 21(10 Suppl):133s-135s. PubMed ID: 12743128
[TBL] [Abstract][Full Text] [Related]
4. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
5. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
6. Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer.
Minagawa Y; Kigawa J; Kanamori Y; Itamochi H; Terakawa N; Okada M; Kitada F
Gynecol Oncol; 2006 Jun; 101(3):495-8. PubMed ID: 16375950
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
[TBL] [Abstract][Full Text] [Related]
8. Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer.
Vasey PA
J Clin Oncol; 2003 May; 21(10 Suppl):136s-144s. PubMed ID: 12743129
[TBL] [Abstract][Full Text] [Related]
9. Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.
Nomura H; Aoki D; Michimae H; Mizuno M; Nakai H; Arai M; Sasagawa M; Ushijima K; Sugiyama T; Saito M; Tokunaga H; Matoda M; Nakanishi T; Watanabe Y; Takahashi F; Saito T; Yaegashi N;
JAMA Oncol; 2019 Jun; 5(6):833-840. PubMed ID: 30896757
[TBL] [Abstract][Full Text] [Related]
10. Carboplatin-paclitaxel- and carboplatin-docetaxel-induced cytotoxic effect in epithelial ovarian carcinoma in vitro.
Engblom P; Rantanen V; Kulmala J; Grènman S
Cancer; 1999 Nov; 86(10):2066-73. PubMed ID: 10570433
[TBL] [Abstract][Full Text] [Related]
11. Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer.
Ozols RF
Semin Oncol; 1995 Dec; 22(6 Suppl 15):1-6. PubMed ID: 8643963
[TBL] [Abstract][Full Text] [Related]
12. In vitro responses of ovarian cancers to platinums and taxanes.
Kornblith P; Wells A; Gabrin MJ; Piwowar J; Chattopadhyay A; George LD; Ochs RL; Burholt D
Anticancer Res; 2003; 23(1B):543-8. PubMed ID: 12680143
[TBL] [Abstract][Full Text] [Related]
13. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
[TBL] [Abstract][Full Text] [Related]
15. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin versus cisplatin in ovarian cancer.
Alberts DS
Semin Oncol; 1995 Oct; 22(5 Suppl 12):88-90. PubMed ID: 7481869
[TBL] [Abstract][Full Text] [Related]
17. Platinum compounds in the treatment of advanced breast cancer.
Martín M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
18. Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells.
Stamelos VA; Robinson E; Redman CW; Richardson A
Gynecol Oncol; 2013 Feb; 128(2):377-82. PubMed ID: 23168176
[TBL] [Abstract][Full Text] [Related]
19. Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial.
Potamianou A; Androulakis N; Papakotoulas P; Toufexi H; Latoufis C; Kouroussis C; Christofilakis C; Xenidis N; Georgoulias V; Polyzos A
Oncology; 2005; 69(4):348-53. PubMed ID: 16293974
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]